27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. 3 key findings →
Design: phase-2-trial Participants: 75 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
A 2-hour infusion of 0.1 to 10 mg/kg ponezumab was well tolerated in subjects with mild-to-moderate AD. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study indicates no benefits for memantine in the long-term treatment and prophylaxis of clinically significant neuropsychiatric symptoms. 5 key findings →
Participants: 199 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. 4 key findings →
Design: cross-sectional Participants: 1,120 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The innate immune system is a viable target for therapeutic intervention in AD. 5 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. 5 key findings →
Design: RCT Participants: 29 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. 1 key finding →
Design: longitudinal study Participants: 337 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden. 4 key findings →
Design: clinical trial Participants: 361 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
C9orf72 mutations are the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
APs appear to increase the risk of hip fracture among older adults with dementia residing in an NH. 3 key findings →
Design: case-control study Participants: 586 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Nilotinib is safe and achieves pharmacologically relevant cerebrospinal fluid concentrations. 4 key findings →
Design: clinical trial Participants: 37 Evidence: high
Full summary, score breakdown and related studies → Original source
To review the optimality and safety of different anti-Amyloid- β (Aβ) immunotherapies for Alzheimer's disease (AD). 3 key findings →
Participants: 5,141 Evidence: high
Full summary, score breakdown and related studies → Original source
Lecanemab may have a significant potential for AEs. 4 key findings →
Participants: 193 Evidence: low
Full summary, score breakdown and related studies → Original source
Four signal calculation methods were used to assess potential adverse reaction signals of lecanemab and aducanumab. 2 key findings →
Participants: 1,409 Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundLecanemab reduces amyloid levels and modestly slows cognitive decline in a large cohort of early Alzheimer's disease (AD) but lacks real-world safety data in Chinese population. 3 key findings →
Participants: 190 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Though these findings cannot prove causality, and we cannot rule out the possibility of residual confounding, they provide more evidence of the risk of using these drugs in older patients, reinforcing the concept that they should not be used in the absence of clear need. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings suggest that long-term use of BZDs is associated with an increased risk for dementia, but the underlying mechanisms remain unclear, and further investigations are needed. 3 key findings →
Design: case-control study Participants: 779 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A safe and effective medicine, huperzine Alpha remarkably improves the cognition, behavior, ADL,and mood of AD patients. 2 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Genetic mutations in TAR DNA-binding protein 43 (TARDBP, also known as TDP-43) cause amyotrophic lateral sclerosis (ALS), and an increase in the presence of TDP-43 (encoded by TARDBP) in the cytoplasm is a prominent histopathological feature of degenerating neurons in various neurodegenerative diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study evaluated efficacy and safety of donepezil hydrochloride (donepezil) at 5 mg/day in patients with mild to moderately severe Alzheimer's disease for 24 weeks in a double-blind, placebo-controlled comparative trial. 4 key findings →
Participants: 228 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 325 participants enrolled and received study drug. 5 key findings →
Participants: 320 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of the total of 1795 subjects randomized in Clarity AD, 294 subjects were in the Asian region (Japan:152; Korea:129; Singapore:13). 5 key findings →
Design: clinical trial Participants: 294 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alterations in α-synuclein dosage lead to familial Parkinson's disease (PD), and its accumulation results in synucleinopathies that include PD, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The proposed rating scale provides a reliable and easily implemented instrument to grade ARIA-E imaging findings. 1 key finding →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
9 of the 468 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →